Back to OTSKFView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
2 competitors in Attention Deficit/Hyperactivity Disorder
View Full LandscapeDrug Information
Target Indication
Attention Deficit/Hyperactivity Disorder
Clinical Trial
NCT05428033Last updated: 12/17/2025
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
EB-1020 (Centanafadine) 328.8 mgPhase 3
Attention Deficit Hyperactivity Disorder (ADHD)
JNT-517 TabletPhase 3
Phenylketonuria (PKU)
Brexpiprazole, OPC-34712Phase 3
Agitation Associated With
ProbucolPhase 3
Hyperlipidemia
Centanafadine HydrochloridePhase 3
Attention-Deficit/Hyperactivity Disorder
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts